Healthcare analysts chimed in on Bioline RX Ltd (NASDAQ:BLRX) and Endo International plc – Ordinary Shares (NASDAQ:ENDP), as both stocks are among the top performers today. The analysts reflect on Bioline’s worldwide agreement with BGN Technologies and Hadasit, and Endo’s CEO transition. Let’s take a closer look:

Bioline RX Ltd

Bioline shares jumped nearly 25% after the company announced that it has signed an exclusive, worldwide agreement with BGN Technologies and Hadasit for the in-licensing of a novel treatment for various liver failure conditions such as end-stage liver disease and for conditions potentially leading to liver failure such as non-alcoholic steatohepatitis.

Roth Capital’s healthcare analyst Joseph Pantginis commented, “An unmet medical need exists for NAFLD and NASH as there are no FDA-approved treatments. In addition to chronic conditions leading to liver injury, BL-1220 may be directed toward regeneration of normal liver in acute liver injury which may expand indications it is approved for. A third of liver transplants are caused by NASH and it is expected to be the principal cause for transplantation by 2020. We believe that a therapeutic agent that halts the progression of NASH therefore preventing ESLD and HCC that may result in a transplant will be of great clinical benefit.”

“BL-1220, is the second project in-licensed under the framework of the strategic collaboration with Novartis Pharma AG for the screening and development of novel drug candidates which achieves the millstone the company set, which was to in-license an additional project by the end of 2016,” the analyst added.

As such, Pantginis reiterated a Buy rating on shares of Bioline, with a price target of $7.00, which implies an upside of 456% from current levels.

According to, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Joseph Pantginis has a yearly average return of 7.6% and a 39% success rate. Pantginis has a -20.3% average return when recommending BLRX, and is ranked #333 out of 4189 analysts.

Endo International plc – Ordinary Shares

Endo shares rose nearly 16% on Friday, following the news that Rajiv De Silva has stepped down as President and CEO, and will be replaced by Paul Campanelli, the current President of Endo’s Generics and OTC business and former CEO of Par.

Mizuho top analyst Irina Rivkind Koffler noted, “We are not surprised by this transition as Mr. De Silva’s skill set may not be helpful to the new direction of this company and we had been wondering about this issue since 1Q:16. We continue to believe that Endo may be restructured and eventually sold to a larger generic player, which may be easier to achieve under new mgmt.”

“Endo reaffirmed its prior guidance: 3Q:16 revenues of $830-$870M and EPS of $0.77-$0.82 vs. consensus $864.5M and $0.81 and our estimates $884.2M and $0.83, and FY:16 revs $3.87-$4.03B and EPS $4.50-$4.80 vs. consensus $3.93B and $4.56 and our estimates $3.97B and $4.52,” the analyst continued.

Koffler rates Endo shares a Buy with a price target of $29, which represents a potential upside of 24% from where the stock is currently trading. Koffler has a very good TipRanks score with a 55% success rate and she stands at #38 out of 4,189 on the analyst leaderboard. Out of the 20 analysts polled by TipRanks, 10 rate Endo stock a Buy, while 10 rate the stock a Hold. With a return potential of 70%, the stock’s consensus target price stands at $39.94.